Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06353906 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Carboplatin/Paclitaxel + Pembrolizumab for Locoregionally Advanced Penile Cancer

Study acronym: PRIAM
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Site details revised at 1 of 2 sitesv5
  2. Study sites: 1 to 2v4
  3. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 1 · Start date changed from estimate of Aug 30, 2024 to Aug 13, 2024v3 Show 2 more changesShow less
    • Study sites: 0 to 1
    • Start date changed from estimate of Aug 30, 2024 to Aug 13, 2024
  4. Start date: Jun 14, 2024 to Aug 30, 2024v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a single-armed, single-centre, non-blinded phase II trial to assess efficacy of induction chemo-immunotherapy for resectable node-positive squamous cell carcinoma of the penis
Trial Details
NCT Number NCT06353906
Lead Sponsor The Netherlands Cancer Institute
Collaborators: Merck Sharp & Dohme LLC
Conditions Urologic Neoplasms, Urogenital Neoplasms, Male Urogenital Diseases, Penile Cancer, Penile Squamous Cell Carcinoma, Locally Advanced Penile Carcinoma
Enrollment 27 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov